Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell massBart Keymeulen, Daniël Pipeleers, Frans Gorus et al.|Diabetologia|2010Cited by 313
Transient reactivation of Epstein-Barr virus in non chronically immunosupressed patients undergoing a short treatment with a humanized non mitogenic CD3 antibodyBart Keymeulen, Lucienne Chatenoud, Sophie Candon et al.|VUBIR (Vrije Universiteit Brussel)|2006Cited by 0